MENU

Zachary Frosch, MD, MSHP

This physician is not currently rated. Why?

Why is this doctor not rated?

Close

To ensure the accuracy of our patient satisfaction scores, we require that providers who see patients receive a minimum number of completed patient-submitted surveys before their reviews are listed on their profiles. Star ratings on this site are collected on a rolling basis from the previous 12 months.
Additionally, some of the physicians listed on our site do not see patients directly, and therefore, do not receive evaluation and ratings from patients.

More about patient ratings

Clinical Locations

Primary Location

Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111

About

Assistant Professor, Department of Hematology/Oncology

Specialties

Treatment Focus

Hodgkin's and Non-Hodgkin's Lymphoma; Chronic Lymphocytic Leukemia

Key Awards

  • 2021 - American Society of Clinical Oncology/Conquer Cancer Foundation Young Investigator Award

Treatment Philosophy

Receiving a cancer diagnosis and starting treatment can be overwhelming. Guiding patients through this difficult process is what first drew me to oncology. I work to help my patients understand their cancer and the different ways we can treat it. I also have a focus on teaching and education, which informs how I approach each conversation with my patients.

In addition to caring for patients, I conduct research in cancer care delivery, aiming to make the process of receiving cancer care simpler, faster, and more accessible to our patients.

Education and Training

Educational Background

  • 2019-2021 - MS, Health Policy Research, Perelman School of Medicine, University of Pennsylvania
  • 2010-2014 - MD, Perelman School of Medicine, University of Pennsylvania
  • 2004-2008 - BA, Wesleyan University

Certifications

  • 2021 - ABIM Board Eligible: Medical Oncology
  • 2021 - ABIM Board Eligible: Hematology
  • 2017 - ABIM Board Certification: Internal Medicine

Memberships

  • 2013-Present - American Society of Hematology
  • 2017-Present - American Society of Clinical Oncology

Honors & Awards

  • 2021 - American Society of Clinical Oncology/Conquer Cancer Foundation Young Investigator Award
  • 2020 - American Society of Clinical Oncology/Conquer Cancer Foundation Merit Award
  • 2017 - American Society of Clinical Oncology/Conquer Cancer Foundation Merit Award
  • 2016 - Martin P. Solomon Primary Care Scholarship Award, Brigham and Women’s Hospital
  • 2013 - American Society of Hematology Abstract Achievement Award
  • 2008 - Walkley Prize for Outstanding Research in Psychology at Wesleyan University
  • 2008 - Graham Prize for Excellence in the Natural Sciences at Wesleyan University
Research Profile

Research Interests

  • Health services research
  • Cancer care delivery
  • Access to cancer treatment and cancer care disparities

Lab Overview

My research focuses on cancer care delivery. This work aims to make the process of receiving cancer care simpler, faster, and more accessible to patients. Recently, I have focused on two key areas: facilitating timely access to cancer treatment, and reducing disparities in the use of specialized therapies that are only available at certain cancer centers. My research is collaborative and draws on techniques from multiple disciplines. These include the analysis of cancer registry and electronic health record data, surveys, qualitative interviews, predictive analytics, and implementation science.

Publications

Selected Publications

Frosch ZAKF, Illenberger N, Mitra N et al. Trends in Patient Volume by Hospital Type and the Association of These Trends With Time to Cancer Treatment Initiation. JAMA Netw Open. 2021.

Hawrot K, Shulman LN, Bleiweiss IJ, Wilkie EJ, Frosch ZAK, Jankowitz RC, Laughlin AI. Time to Treatment Initiation for Breast Cancer During the 2020 COVID-19 Pandemic. JCO Oncol Pract. 2021 Mar 12;:OP2000807. doi: 10.1200/OP.20.00807. [Epub ahead of print] PubMed PMID: 33710914.

Frosch ZAK, Shulman LN, Bekelman JE. Independent Oncology Practices in the COVID-19 Era-Does US Cancer Care Need a Bailout?. JAMA Oncol.2021 Mar 1;7(3):347-348. doi: 10.1001/jamaoncol.2020.4753. PubMed PMID: 33090180.

Frosch ZAK, Landsburg DJ. Molecular Risk Stratification in Aggressive B-Cell Lymphomas. J Clin Oncol. 2020 Jun 20;38(18):2014-2017. doi: 10.1200/JCO.19.03069. Epub 2020 Apr 2. PubMed PMID: 32243222; PubMed Central PMCID: PMC7302956.

Frosch ZAK, Cronin AM, Gagne JJ, Teschke MP, Gray SW, Abel GA. Cancer drug shortages: Awareness and perspectives from a representative sample of the US population. Cancer. 2018 May 15;124(10):2205-2211. doi: 10.1002/cncr.31246. Epub 2018 Apr 8. PubMed PMID: 29635808.

Frosch ZAK, Gagne JJ, Gray SW, Abel GA. What Does a Cancer Diagnosis Mean? Public Expectations in a Shifting Therapeutic Environment. J Oncol Pract. 2018 Mar;14(3):139-140. doi: 10.1200/JOP.17.00009. Epub 2018 Jan 30. PubMed PMID: 29381410.

Frosch Z, Luskin MR, Landsburg DJ, Schuster SJ, Svoboda J, Loren AW, Porter DL, Stadtmauer EA, Nasta SD. R-CHOP or R-HyperCVAD with or without autologous stem cell transplantation for older patients with mantle cell lymphoma. Clin Lymphoma Myeloma Leuk. 2015 Feb;15(2):92-7. doi: 10.1016/j.clml.2014.07.017. Epub 2014 Aug 1. PubMed PMID: 25174772.

Frosch ZA, Abel GA. Assessing Quality of Care for the Myelodysplastic Syndromes. Curr Hematol Malig Rep. 2016 Dec;11(6):402-407. doi: 10.1007/s11899-016-0343-0. Review. PubMed PMID: 27562670.

Additional Publications

MyNCBI

Connect with Fox Chase